Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Biogen Inc.

Biogen Inc. (BIIB) Stock Overview

Explore Biogen Inc.’s financial performance, market position, analyst ratings, and future outlook.

BIIB●NASDAQ
HealthcareDrug Manufacturers - General
$253.62
$3.97(1.59%)
U.S. Market opens in 54h 16m

Biogen Inc. (BIIB)

Meyka AI Score

Z

Key Financials

Market Cap37.5B
P/E Ratio106.76
EPS (TTM)$15.84
ROE0.02%
Fundamental Analysis

AI Price Forecasts

1 Month$253.60
3 Months$261.93
1 Year Target$180.15

BIIB Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Biogen Inc. (NASDAQ: BIIB) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Biogen Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of BIIB on the NASDAQ shows an RSI of 66.88, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $180.15 for the NASDAQ listing.

Key metrics behind Biogen Inc.'s NASDAQ-traded stock include a P/E ratio of 106.76 and a market capitalization of 37.5B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BIIB on the NASDAQ.

Price Performance (NASDAQ: BIIB)

1-Day Change
1.60%
5-Day Change
0.78%
1-Month Change
12.29%
3-Month Change
21.99%
6-Month Change
34.008%
Year-to-Date (YTD) Change
44.13%
1-Year Change
69.54%
3-Year Change
6.93%
5-Year Change
-6.78%
All-Time (Max) Change
8016.80%

Contact Information

https://www.biogen.com
617 679 2000
225 Binney Street, Cambridge, MA, 02142

Company Facts

75,000 Employees
IPO DateSep 17, 1991
CountryUS
Actively Trading

Frequently Asked Questions